Research and Clinical Trials

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder
Brief Description  
The purpose of the study is to evaluate the long-term safety and tolerability of compound TC-5214 compared with placebo as an add on to antidepressant therapy in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy.
Who may be Eligible  
Male and female patients diagnosed with Major Depressive Disorder 18 to 65 years of age with an inadequate response to antidepressant therapy within the current episode. Patients who have not been treated with a permitted antidepressant can enroll into a 6-week prospective open-label period. These patients will receive treatment with an open-label antidepressant therapy selected by the investigator to demonstrate inadequate response.
Major Depressive Disorder
IRB Number  
Principal Investigator  
Tcheremissine, Oleg

For More Information, Contact  Dineen  , Gardner
Phone:  (704) 446-7511  Fax:  (704) 446-7505  
Address:465 North Wendover Road Charlotte, NC 28211